## RECEIVED CENTRAL FAX CENTER

DEC 0 1 2005

SAS:dsh 12/01/05 4239-61854-01 4586\$3 F-104-1999/2-US-15; E-104-1999/2-US-19

PATENT

130

PLEASE DELIVER DIRECTLY TO: EXAMINER RAWLINGS

Fax No.: 1-571-273-8300

Total No. Pages: | including this cover sheet

Message:

Transmitted herewith for filing in the above-identified application is a Supplemental Information Disclosure Statement and attached reference. If you do not receive all

pages or if you have problems receiving transmittal, please call Dawn Hagen at

(503) 226-7391.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 10/031,158 Filed: January 11, 2002 Confirmation No. 8170

T-CELL RECEPTOR Y ALTERNATE

READING FRAME PROTEIN, (TARP)

AND USES THEREOF

Examiner: Stephen L. Rawlings, Ph.D.

Art Unit: 1641

Attorney Reference No. 4239-61854-01

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence and any documents referred to as being transmitted herewith are being facsimile transmitted to the Patent and Trademark Office via 571-273-8300

on December 1, 2005

rgent for Applicant

Dated: December 1, 2005

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

# BEST AVAILABLE COPY

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and attached herewith is an Englishlanguage document. Applicants respectfully request that this document be listed as references cited on the issued patent.

Applicants filed this Supplemental Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this SAS:dsh 12/01/05 4239-61854-01 458613 F-104-1999/2-U\$-15; E-104-1999/2-U\$-19

PATENT

IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 228-9446

cc: Docketing

RECEIVED CENTRAL PAX CENTER

DEC 0 1 2005

SAS:dsh 12/01/05 4239-61854-01 458613 E-104-1999/2-US-15; E-104-1999/2-US-19

PATENT

PLEASE DELIVER DIRECTLY TO: EXAMINER RAWLINGS

Fax No.: 1-571-273-8300

Total No. Pages: \(\) including this cover sheet

Transmitted herewith for filing in the above-identified application is a Supplemental Information Disclosure Statement and attached reference. If you do not receive all pages or if you have problems receiving transmittal, please call Dawn Hagen at

(503) 226-7391.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

**Application No. 10/031,158** 

Filed: January 11, 2002 Confirmation No. 8170

T-CELL RECEPTOR Y ALTERNATE

READING FRAME PROTEIN, (TARP)

AND USES THEREOF

Examiner: Stephen L. Rawlings, Ph.D.

Art Unit: 1641

Attorney Reference No. 4239-61854-01

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence and any documents referred to as being transmitted herewith are being facsimile transmitted to the Patent and Trademark Office via 571-273-8300

on December 1, 200

agent for Applicant

Dated: December 1, 2005

COMMISSIONER FOR PATENTS P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and attached herewith is an Englishlanguage document. Applicants respectfully request that this document be listed as references cited on the issued patent.

Applicants filed this Supplemental Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this SAS:dsh 12/01/05 4239-61854-01 458613 E-104-1999/2-US-15; E-104-1999/2-US-19

**PATENT** 

IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Rν

Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 228-9446

cc: Docketing

SAS:dsh 12/01/05 4239-61854-01 458607 E-104-1999/2-US-15; E-104-1999/2-US-19

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Attorney Docket Number	4239-61854-01
			Application Number	10/031,158
			Filing Date	January 11, 2002
			First Named Inventor	Pastan
			Art Unit	1641
			Examiner Name	Stephen L. Rawlings
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
-		WOLFGANG et al., "TARP: A nuclear protein expressed in prostate and breast cancer		
		cells derived from an alternate reading frame of the T cell receptor $\gamma$ chain locus," <i>Proc.</i>		or γ chain locus," <i>Proc.</i>
		Natl. Acad. Sci USA, 97(17):9437-94	442 (2000)	
		•		
			· - · · · · · · · · · · · · · · ·	
·				
	,			
<del></del>		,	11 11 11 11 11 11	
<del></del> -				
	-			
Page 1				
	1			

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.